Redeye views favorably on the order received by the subsidiary Citilog to deliver its AI and Deep Le...
Redeye comments on Ortoma’s agreement with DePuy Synthes.
Redeye provides a research update following Infracom’s acquisitions of ComCenter.
We have now included acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) in our sum-of-...
Redeye comments on Infracom’s acquisitions of ComCenter, which were announced earlier today.
Today, BankNordik upgraded its FY 2023E net profit guidance from DKK 235-265m to DKK 260-290m, corre...
Redeye views today's press release positively, stating that Lifecare has received development fundin...
Redeye provides a comment on the announcement of a potential indication expansion made by Initiator ...
Positiva data från fas 2-studien med ACD440 presenterades.
STENOCARE announced on September 18th a market update highlighting progress in several areas, includ...
With the upcoming 88% guaranteed SEK 80m rights issue, plus SEK 23m in credit, Agtira is gearing up ...
Redeye leaves a comment on yesterday’s announcement stating that Newbury has successfully signed a S...
Redeye attended Impact Coatings’ capital markets update yesterday.
Redeye updates its estimates and fair value range following Arise’s capital markets day and the new ...
Redeye comments on Evaxion’s collaboration with a leading pharmaceutical company.
Redeye argues that the recent news regarding Integrum’s review and evaluation of strategic alternati...
Redeye is enthusiastic by today’s news of the FDA expanding the approval for Catalyst to interbody c...
This morning, Vow announced that the company has been awarded three contracts in its Industrial segm...
Redeye expresses a favourable perspective regarding the acquisition of IIOOTE AB, recognising its ca...
Ascelias priority is to secure a re-reader evaluation of SPARKLE by May 2024.
